[go: up one dir, main page]

AR089130A1 - FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO - Google Patents

FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO

Info

Publication number
AR089130A1
AR089130A1 ARP120104624A ARP120104624A AR089130A1 AR 089130 A1 AR089130 A1 AR 089130A1 AR P120104624 A ARP120104624 A AR P120104624A AR P120104624 A ARP120104624 A AR P120104624A AR 089130 A1 AR089130 A1 AR 089130A1
Authority
AR
Argentina
Prior art keywords
extended release
dosage form
caprolactone
solid
polyethylene oxide
Prior art date
Application number
ARP120104624A
Other languages
English (en)
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of AR089130A1 publication Critical patent/AR089130A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma de dosis farmacéutica de liberación extendida sólida, que comprende una mezcla en la forma de una formulación matricial de liberación extendida, donde la mezcla comprende al menos: (1) al menos una poli(e-caprolactona), y (2) al menos un óxido de polietileno, y (3) al menos un agente activo. Reivindicación 1: Una forma de dosis farmacéutica sólida de liberación extendida, que comprende una mezcla en la forma de una formulación matricial de liberación extendida, donde la mezcla comprende al menos: (1) al menos una poli(e-caprolactona) con un peso molecular promedio aproximado desde alrededor de 10.000 a alrededor de 200.000, y (2) al menos un óxido de polietileno con un peso molecular promedio aproximado de alrededor 10.000 a menos que 1.000.000, y (3) al menos un agente activo. Reivindicación 62: La forma de dosis farmacéutica sólida de liberación extendida de acuerdo a cualquiera de las reivindicaciones 1 a 61, donde la formulación matricial de liberación extendida comprende al menos un retardante adicional. Reivindicación 65: La forma de dosis farmacéutica sólida de liberación extendida de la reivindicación 64, donde el retardante es behenato de glicerilo. Reivindicación 76: La forma de dosis farmacéutica sólida de liberación extendida de acuerdo a la reivindicación 75, donde el analgésico opioide es seleccionado desde el grupo consistente de codeína, morfina, oxicodona, hidrocodona, hidromorfona, oximorfona, las sales, hidratos, solvatos y mezclas farmacéuticamente aceptables de los anteriores. Reivindicación 92: La forma de dosis farmacéutica sólida de liberación extendida de acuerdo a la reivindicación 91, donde el antagonista opioide es seleccionado del grupo consistente de naloxona, naltrexona, nalmefeno, y sales, hidratos solvatos y mezclas farmacéuticamente aceptables de los anteriores.
ARP120104624A 2011-12-09 2012-12-10 FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO AR089130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161569193P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
AR089130A1 true AR089130A1 (es) 2014-07-30

Family

ID=47522734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104624A AR089130A1 (es) 2011-12-09 2012-12-10 FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO

Country Status (10)

Country Link
US (2) US20150265536A1 (es)
EP (1) EP2787978B1 (es)
JP (1) JP6144274B2 (es)
CN (2) CN104010630A (es)
AR (1) AR089130A1 (es)
AU (1) AU2012327231B2 (es)
CA (1) CA2858868C (es)
ES (1) ES2603278T3 (es)
TW (1) TW201336529A (es)
WO (1) WO2013084059A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) * 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
SG11201804384UA (en) 2015-12-08 2018-06-28 Lyndra Inc Geometric configurations for gastric residence systems
EP3181124A1 (en) * 2015-12-16 2017-06-21 Universität Basel Abuse deterrent pharmaceutical dosage forms
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2557459B1 (fr) * 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
FR2701152B1 (fr) 1993-02-03 1995-03-10 Digipress Sa Procédé de fabrication d'un disque maître pour la réalisation d'une matrice de pressage notamment de disques optiques, matrice de pressage obtenue par ce procédé et disque optique obtenu à partir de cette matrice de pressage.
EP0950690B1 (en) * 1996-11-05 2005-01-26 NOVAMONT S.p.A. Biodegradable polymeric compositions comprising starch and a thermoplastic polymer
AU776904B2 (en) * 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020007013A1 (en) * 2000-05-16 2002-01-17 Cohen Gordon Mark Compositions containing elastomeric ethylene or (meth)acrylic ester copolymers
WO2004064807A1 (en) * 2003-01-23 2004-08-05 Amorepacific Corporation Sustained-release preparations and method for producing the same
AU2004222339A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
PL1718258T3 (pl) * 2004-02-23 2009-08-31 Euro Celtique Sa Odporne na nadużywanie transdermalne urządzenie do podawania opioidu
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1888038A2 (en) * 2005-05-10 2008-02-20 Novartis AG Modified release famciclovir pharmaceutical compositions
JP5586151B2 (ja) * 2005-12-13 2014-09-10 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド 乱用抵抗性経粘膜薬剤送達デバイス
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)

Also Published As

Publication number Publication date
JP2015500273A (ja) 2015-01-05
TW201336529A (zh) 2013-09-16
WO2013084059A1 (en) 2013-06-13
US20200170954A1 (en) 2020-06-04
CN107854434A (zh) 2018-03-30
EP2787978B1 (en) 2016-09-21
CN104010630A (zh) 2014-08-27
AU2012327231A1 (en) 2013-06-27
CA2858868C (en) 2017-08-22
CA2858868A1 (en) 2013-06-13
ES2603278T3 (es) 2017-02-24
EP2787978A1 (en) 2014-10-15
AU2012327231B2 (en) 2015-09-24
US20150265536A1 (en) 2015-09-24
JP6144274B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
AR089130A1 (es) FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO
AR095160A1 (es) Formulaciones farmacéuticas a prueba de alteraciones
JP2015044834A5 (es)
JP2011137020A5 (es)
JP2013151541A5 (es)
AR088250A1 (es) Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide
AR095343A1 (es) Cápsula resistente a su uso indebido por administración parenteral de principios activos
JP2016014040A5 (es)
PE20220581A1 (es) Composicion farmaceutica para suministro nasal
EA032906B1 (ru) Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения
RU2013117274A (ru) Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
PE20141671A1 (es) Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
AR084620A1 (es) Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
AR092820A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
PE20190391A1 (es) Formas de dosificacion del tapentadol novedosas y potentes
MX2013008225A (es) Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.
CO6341547A2 (es) Uso de antagonistas opioides para el tratamiento de retencion urinaria
RU2016123972A (ru) Применение антагониста опиоидных рецепторов с к-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
NZ603170A (en) Combination of active loaded granules with additional actives
JP2013537915A5 (es)
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
HRP20110049T2 (hr) Opioidi za liječenje nemirnosti kod donjih ekstremiteta

Legal Events

Date Code Title Description
FA Abandonment or withdrawal